XPO1 and small cell lung carcinoma: In vivo, the XPO1 inhibitor, combined with chemotherapy, demonstrated stronger anti-tumor effects and prolonged survival in SCLC compared with chemotherapy alone, suggesting that the combination of selinexor with either cisplatin or irinotecan may have beneficial effects and an acceptable toxicity profile.